对BCL-2的依赖是慢性淋巴细胞白血病治疗反应的有利预测标志物
Stephen Jun Fei Chong1,2,3, Junyan Lu4, Rebecca Valentin1,5
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Molecular cancer
|March 2, 2025
概括
慢性淋巴细胞白血病 (CLL) 治疗反应可以通过BCL-2依赖性预测,这是一个功能性生物标志物. 这一发现有助于个性化治疗选择超越遗传标记,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 精准医学是一门精准的医学.
背景情况:
- 已确立的慢性淋巴细胞白血病 (CLL) 的遗传生物标志物预测化学免疫治疗反应,但不能预测向治疗的疗效.
- 需要新的非遗传预测生物标志物来指导CLL的最佳向治疗选择.
研究的目的:
- 确定慢性淋巴细胞白血病 (CLL) 治疗反应的新型非遗传预测生物标志物.
- 评估BCL-2依赖性作为一个功能性生物标志物,用于预测CLL中针对性治疗的反应.
主要方法:
- 在73名CLL患者中,结合BH3分析 (评估细胞染色体c损失) 与多omics数据 (测序,甲基化,RNA,蛋白质) 进行.
- 验证了细胞系和54名CLL患者的独立队列中的验证结果,这些患者接受了IBRUTINIB和化学免疫疗法.
主要成果:
- 对抗亡的BCL-2蛋白质的更大依赖与有利的遗传标志物相关,并在CLL中预测了药物反应.
- 对BCL-2的依赖因果关系与基因表达模式和信号通路有关,表明对向药物的敏感性.
- 较高的BCL-2依赖预测了对ibrutinib加上化疗免疫治疗的良好临床反应,无论遗传背景如何.
结论:
- 依赖BCL-2是一种验证的CLL治疗反应的功能和预测生物标志物.
- 鉴定apoptotic信号的特征对于分层CLL患者超越遗传标记至关重要.
- 这种方法有助于优化针对性治疗组合的CLL患者.
更多相关视频
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.0K
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
26.6K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K